Streetbeat News

Price Targets

CRNC

Needham analyst Quinn Bolton has maintained a Buy rating on Cerence Inc. (NASDAQ:CRNC) but has reduced the price target from $34 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:38 pm

CROX

Raymond James analyst Rick Patel upgraded Crocs, Inc. (NASDAQ:CROX) from Outperform to Strong Buy and increased the price target from $98 to $115.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:28 pm

ARCT

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a price target of $51. This reaffirmation of the stock's potential could influence investor sentiment and the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:22 pm

ETNB

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on 89bio (NASDAQ:ETNB) and maintained a $35 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:19 pm

SLRN

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acelyrin (NASDAQ:SLRN) and maintained a $30 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:12 pm

FRLN

HC Wainwright & Co. analyst Patrick Trucchio has downgraded Freeline Therapeutics (NASDAQ:FRLN) from Buy to Neutral and reduced the price target from $15 to $6.5.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:10 pm

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $49 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:06 pm

ANVS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Annovis Bio (NYSE:ANVS) and maintained a $30 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:04 pm

AVXL

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Anavex Life Sciences (NASDAQ:AVXL) and maintained a price target of $54. This reaffirmation of the company's stock suggests confidence in its future performance.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:02 pm

DBI

Analysts have maintained an indifferent stance on Designer Brands (NYSE:DBI) with 5 neutral ratings in the last quarter. The average price target is $11.4, representing an upside from the current price of $10.76. This target has increased by 34.12% from the previous target of $8.50. Analysts determine ratings by forecasting a company's future earnings and stability.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 12:00 pm